arrow_back Back Filing freshness 10-K FY 2026 SEC EDGAR

Sonoma Pharmaceuticals, Inc.

SNOA
$1.42 ▲ +0.19 (+15.45%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
17 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
25
Health
Poor
Bearish
auto_awesome

Analytical Summary

Sonoma Pharmaceuticals, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.4M
Dividend Yield
Revenue Growth 36.7%
Op. Margin -12.6%
ROIC -73.8%
FCF / Share $-2.45
Trailing P/E
Price / Book 0.8x
FCF Yield
Debt / Equity 0.07
info Valuation on last close. End-of-day price, Aug 7, 2026.

17-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$19.53M
↑ +36.7%
Net Income Profit after all expenses
$-3.17M
↑ +8.2%
Operating Margin Operating profit as % of sales
-12.6%
↑ +51.5% 11th
FCF / Share Free cash flow per share
$-2.45
↓ -1709.4%
Long-Term Debt Long-term obligations
$1.31M
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
9
Returns
6
Financial Health
44
Cash Quality
72

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 17 years · 63 quarters